The upcoming World Conference on Lung Cancer, being held in Singapore from 9-12 September, has a number of major readouts in targeted lung cancer therapy and antibody drug conjugates (ADCs) including presentations from AstraZeneca, Daiichi Sankyo and Gilead.
The meeting is particularly important for AstraZeneca, which is looking to extend its dominance in non-small cell lung cancer (NSCLC)...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

